Stockscreener 앱 받기
60.04
0.15%
0.32
시간 외 거래:
59.91
-0.13
-0.22%
전일 마감가:
$59.72
열려 있는:
$55.8
하루 거래량:
710.05K
Relative Volume:
0.96
시가총액:
$4.29B
수익:
$58.89M
순이익/손실:
$-240.88M
주가수익비율:
-19.37
EPS:
-3.1
순현금흐름:
$-239.96M
1주 성능:
-3.45%
1개월 성능:
+3.30%
6개월 성능:
+69.53%
1년 성능:
+27.07%
1일 변동 폭
$55.66
$61.58
1주일 범위
$55.66
$63.36
52주 변동 폭
$19.45
$63.96
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
59.99 | 4.27B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.33 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
627.97 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.26 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.34 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.74 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Oppenheimer raises Kymera Therapeutics stock price target ahead of Phase 1b readout - Investing.com Nigeria
Earnings call transcript: Kymera Therapeutics Q3 2025 misses EPS expectations - Investing.com Philippines
Kymera Q3 2025 slides reveal strong cash position despite earnings miss - Investing.com
Kymera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update - Investing News Network
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q3 Revenue $2.8M, vs. FactSet Est of $23.3M - MarketScreener
Kymera Therapeutics Inc Q3 2025 Earnings: EPS of -$0.94 Misses E - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) completes AD Phase 1b dosing, starts Phase 2b trial - Stock Titan
Kymera Therapeutics Q3 2025 Earnings Preview - MSN
Pattern recognition hints at Kymera Therapeutics Inc. upsideJuly 2025 Opening Moves & Expert Curated Trade Setups - newser.com
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - Investing News Network
Guggenheim Assumes Buy Rating for Kymera Therapeutics (KYMR) | K - GuruFocus
Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - GuruFocus
How to read the order book for Kymera Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Guggenheim assumes coverage on Kymera stock with Buy rating, $90 target - Investing.com Canada
Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts - Stock Titan
How analysts rate Kymera Therapeutics Inc. stock today2025 Year in Review & Stock Portfolio Risk Control - newser.com
Is Kymera Therapeutics Inc. stock supported by innovation pipelineEntry Point & Free Verified High Yield Trade Plans - newser.com
What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
AlphaQuest LLC Acquires New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
34,797 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Moody Aldrich Partners LLC - MarketBeat
Is Kymera Therapeutics Inc. stock attractive for ETFsWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com
Jennison Associates LLC Acquires 272,739 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,829,700.00 in Stock - MarketBeat
How hedge fund analytics apply to Kymera Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing - MarketScreener
KYMR insider trade: CEO option exercise and matching share sales - Stock Titan
Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance
How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance
Is Kymera Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Earnings & Low Volatility Stock Recommendations - Fundação Cultural do Pará
Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative
Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET - Stock Titan
What technical charts say about Kymera Therapeutics Inc. stockJuly 2025 Summary & Community Verified Trade Signals - Fundação Cultural do Pará
Earnings Recap: Why Kymera Therapeutics Inc. stock could outperform in 2025Trend Reversal & Free Expert Approved Momentum Trade Ideas - Fundação Cultural do Pará
Why Kymera Therapeutics Inc. stock could outperform in 2025July 2025 Big Picture & Real-Time Stock Entry Alerts - fcp.pa.gov.br
Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis - TipRanks
Kymera’s IRF5 degrader shows promise in preclinical lupus, RA studies - Investing.com
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting - Investing News Network
Kymera (NASDAQ: KYMR) shows KT-579 IRF5 degrader activity in lupus, RA at ACR - Stock Titan
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.56%
자본화:
|
볼륨(24시간):